Celldex Therapeutics, Inc. (CLDX) — Financial statements
Income statement, balance sheet, and cash flow for Celldex Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↓78.6% | 7↑2.0% | 7↑192.0% | 2↓49.3% | 5 | |
| Cost of Revenue | 0.00↓100.0% | 164↑38.6% | 118↑43.5% | 82↑54.3% | 53 | |
| Gross Profit | 2↑101.0% | -157↓40.9% | -111↓39.1% | -80↓64.2% | -49 | |
| Operating Expenses | ||||||
| R&D Expenses | 245↑49.9% | 164↑38.6% | 118↑43.5% | 82↑44.8% | 57 | |
| General & Administrative Expenses | 44↑13.6% | 39↑24.7% | 31↑13.7% | 27↑32.7% | 20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↑13.6% | 39↑24.7% | 31↑13.7% | 27↑32.7% | 20 | |
| Other Expenses | 0.00↑100.0% | -164↓55.0% | -106↓42.4% | -74↓35.5% | -55 | |
| Operating Expenses | 289↑649.5% | 39↓11.2% | 43↑22.9% | 35↑56.5% | 23 | |
| Total Costs & Expenses | 289↑43.0% | 202↑25.2% | 161↑37.3% | 118↑54.9% | 76 | |
| Operating Results | ||||||
| Operating Income | -287↓47.3% | -195↓26.2% | -155↓34.1% | -115↓61.7% | -71 | |
| Depreciation & Amortization | 3↑6.4% | 3↑5.6% | 3↑3.9% | 3↓5.6% | 3 | |
| EBITDA | -255↓33.1% | -192↓38.0% | -139↓33.4% | -104↓57.7% | -66 | |
| EBIT | -259↓32.7% | -195↓37.3% | -142↓32.6% | -107↓54.9% | -69 | |
| Interest & Other Income | ||||||
| Net Interest Income | 29↓23.1% | 37↑183.8% | 13↑350.8% | 3↑476.0% | 0.51 | |
| Interest Income | 29↓23.1% | 37↑183.8% | 13↑350.8% | 3↑476.0% | 0.51 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -29 | 0.00↑100.0% | -13↓53.6% | -8↓288.4% | -2 | |
| Other Income / Expenses | 29↓23.1% | 37↑183.8% | 13↑350.8% | 3↑476.0% | 0.51 | |
| Income Before Tax | -259↓63.9% | -158↓11.6% | -141↓25.9% | -112↓58.8% | -71 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.23 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -259↓63.9% | -158↓11.6% | -141↓25.9% | -112↓59.3% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -259↓63.9% | -158↓11.6% | -141↓25.9% | -112↓59.3% | -71 | |
| Bottom-Line Net Income | -259↓63.9% | -158↓11.6% | -141↓25.9% | -112↓59.3% | -71 | |
| EPS (Basic) | -3.90↓59.2% | -2.45↑16.1% | -2.92↓21.7% | -2.40↓46.3% | -1.64 | |
| EPS (Diluted) | -3.90↓59.2% | -2.45↑16.1% | -2.92↓21.7% | -2.40↓46.3% | -1.64 | |
| Weighted Average Shares | 67↑3.3% | 64↑32.9% | 48↑3.3% | 47↑9.4% | 43 | |
| Weighted Average Diluted Shares | 67↑3.3% | 64↑32.9% | 48↑3.3% | 47↑9.4% | 43 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.